Evidence map›Paper›PMID 26230706›Full record

ArticleViruses2015

Evaluation of Trichodysplasia Spinulosa-Associated Polyomavirus Capsid Protein as a New Carrier for Construction of Chimeric Virus-Like Particles Harboring Foreign Epitopes.

Alma Gedvilaite, Indre Kucinskaite-Kodze, Rita Lasickiene, Albertas Timinskas, Ausra Vaitiekaite, Danguole Ziogiene, Aurelija Zvirbliene

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Alma GedvilaiteVilnius University Institute of Biotechnology, V.A. Graiciuno 8, Vilnius LT-02241, Lithuania. alma.gedvilaite@bti.vu.lt.
Indre Kucinskaite-KodzeVilnius University Institute of Biotechnology, V.A. Graiciuno 8, Vilnius LT-02241, Lithuania. indre.kodze@bti.vu.lt.
Rita LasickieneVilnius University Institute of Biotechnology, V.A. Graiciuno 8, Vilnius LT-02241, Lithuania. rita.lasickiene@bti.vu.lt.
Albertas TiminskasVilnius University Institute of Biotechnology, V.A. Graiciuno 8, Vilnius LT-02241, Lithuania. albertas.timinskas@bti.vu.lt.
Ausra VaitiekaiteVilnius University Institute of Biotechnology, V.A. Graiciuno 8, Vilnius LT-02241, Lithuania. ausra.vaitiekaite@bti.vu.lt.
Danguole ZiogieneVilnius University Institute of Biotechnology, V.A. Graiciuno 8, Vilnius LT-02241, Lithuania. danguole.ziogiene@bti.vu.lt.
Aurelija ZvirblieneVilnius University Institute of Biotechnology, V.A. Graiciuno 8, Vilnius LT-02241, Lithuania. aurelija.zvirbliene@bti.vu.lt.
Vilnius University · LT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recombinant virus-like particles (VLPs) represent a promising tool for protein engineering. Recently, trichodysplasia spinulosa-associated polyomavirus (TSPyV) viral protein 1 (VP1) was efficiently produced in yeast expression system and shown to self-assemble to VLPs. In the current study, TSPyV VP1 protein was exploited as a carrier for construction of chimeric VLPs harboring selected B and T cell-specific epitopes and evaluated in comparison to hamster polyomavirus VP1 protein. Chimeric VLPs with inserted either hepatitis B virus preS1 epitope DPAFR or a universal T cell-specific epitope AKFVAAWTLKAAA were produced in yeast Saccharomyces cerevisiae. Target epitopes were incorporated either at the HI or BC loop of the VP1 protein. The insertion sites were selected based on molecular models of TSPyV VP1 protein. The surface exposure of the insert positions was confirmed using a collection of monoclonal antibodies raised against the intact TSPyV VP1 protein. All generated chimeric proteins were capable to self-assemble to VLPs, which induced a strong immune response in mice. The chimeric VLPs also activated dendritic cells and T cells as demonstrated by analysis of cell surface markers and cytokine production profiles in spleen cell cultures. In conclusion, TSPyV VP1 protein represents a new potential carrier for construction of chimeric VLPs harboring target epitopes.

Indexed as

Drug CarriersAnimalsCapsid ProteinsDendritic CellsEpitopes, B-LymphocyteEpitopes, T-LymphocyteFemaleHepatitis B AntibodiesHepatitis B virusMice, Inbred BALB CPolyomavirusRecombinant Fusion ProteinsSaccharomyces cerevisiaeT-LymphocytesVaccines, SyntheticVaccines, Virus-Like ParticleCapsid ProteinsDrug CarriersEpitopes, B-LymphocyteEpitopes, T-LymphocyteHepatitis B AntibodiesRecombinant Fusion ProteinsVaccines, SyntheticVaccines, Virus-Like ParticleChimeric virus-like particlesimmunogenicitypolyomavirusesTSPyV VP1 protein

Identifiers

PMID26230706
PMCPMC4576179
OpenAlexW2151474520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.